1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.9740/mhc.2019.03.076" target="_blank" rel="noreferrer noopener">http://doi.org/10.9740/mhc.2019.03.076</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
76-81
Issue
2
Volume
9
NEOMED College
NEOMED College of Pharmacy; NEOMED College of Medicine
NEOMED Department
Department of Pharmacy Practice; Department of Psychiatry
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Evaluation of dextromethorphan with select antidepressant therapy for the treatment of depression in the acute care psychiatric setting.
Publisher
An entity responsible for making the resource available
The mental health clinician
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
2019-03
Subject
The topic of the resource
depression; NMDA; fluoxetine; bupropion; CYP2D6 inhibitor; dextromethorphan; paroxetine
Creator
An entity primarily responsible for making the resource
Nofziger Jill L; Paxos Chris; Emshoff Jessica; Mullen Chanda
Description
An account of the resource
Introduction: Dextromethorphan (DXM), an N-methyl-D-aspartate receptor antagonist, may have ketamine-like antidepressant effects. Dextromethorphan is extensively metabolized via cytochrome P450 (CYP) 2D6, and its half-life in extensive metabolizers is 2 to 4 hours. The purpose of this study was to evaluate the effects of DXM in combination with a moderate-to-strong CYP2D6 inhibitor antidepressant on depression in an acute care psychiatric setting. Methods: This was a single-center, retrospective chart review of adult patients with a depressive disorder diagnosis. Patients who received select antidepressant therapy with or without scheduled DXM were included. The primary outcome was the difference in time to improvement of depressive symptoms, which was an average composite of physician documentation, nurse documentation, and first time to 24 hours without as-needed anxiolytics or antipsychotics. The study group consisted of patients who received DXM with select antidepressant therapy, whereas the control group included those who received only select antidepressant therapy. Results: A total of 40 patients were included. The median time to clinical improvement was 3.00 days and 2.83 days for the study group and control group, respectively (P = .986). The incidence of perceptual disturbances and delusions was higher in the study group as compared with the control group (55% and 35% vs 30% and 25%, respectively). Discussion: Dextromethorphan was not associated with a rapid antidepressant effect. The commonly used dose of 30 mg daily may have been too low to have an effect; additionally, the most frequently utilized select antidepressant, bupropion, has moderately less CYP2D6 inhibition than fluoxetine and paroxetine.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.9740/mhc.2019.03.076" target="_blank" rel="noreferrer noopener">10.9740/mhc.2019.03.076</a>
2019
bupropion
CYP2D6 inhibitor
Department of Pharmacy Practice
Department of Psychiatry
Depression
dextromethorphan
Emshoff Jessica
fluoxetine
Mullen Chanda
NEOMED College of Medicine
NEOMED College of Pharmacy
NMDA
Nofziger Jill L
paroxetine
Paxos Chris
The mental health clinician